Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

The goal of this clinical trial es to learn about the short term effects of intravitreal dexamethasone implant (IDI) in patients with refractory diabetic macular edema. The main question it aims to answer is:

How fast does the diminishing in central retinal thickness has statistical significance after IDI in patients with refractory diabetic macular edema? Patients will be evaluated by OCT before and after the implant.

Patients were evaluated at baseline, 2 hours, 3 hours, 24 hours, 1 week and 1 month post IDI

Inclusion Criteria:

• patients with type 1 or type 2 diabetes
• diabetic macular edema involving the foveal center with CRT >300 μm measured by OCT
• at least 3 and maximum 9 monthly intravitreal injections of anti-VEGF

Exclusion Criteria:

• uncontrolled diabetes (blood glucose ≥ 250 mg/dL at any time
• previous IDI
• any condition precluding adequate fundus visualization
• uncontrolled glaucoma
• papillary excavation ≥ 0.7